STAB2

Across TCGA pan-cancer cohorts, STAB2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated STAB2 data layer compared with 23 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher STAB2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated STAB2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where STAB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.917	0.225	.024	12	view →
LUAD	OS	Quartile	II,III,IV	0.306	0.798	.008	6	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.200	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

STAB2–PDAC (OS)

Open the PDAC breakdown →